Literature DB >> 7806829

Hyperbaric oxygen for perianal Crohn's disease.

A Lavy1, G Weisz, Y Adir, Y Ramon, Y Melamed, S Eidelman.   

Abstract

Perianal involvement in Crohn's disease is common (< or = 50%), distressing, and frequently refractory to treatment. Clinical features include painful induration and stenosis, discharging fistulas, and fissures. The pathogenesis of these lesions is unclear, but local ischemia and secondary anaerobic infection may play a role. Following three sporadic reports of successful treatment with hyperbaric oxygen (HBO), we undertook a trial of this method in 10 patients with refractory perianal disease. These patients' perianal Crohn's disease had not responded to treatment that included local medications, salicylates, corticosteroids, metronidazole, or 6-mercaptopurine were treated. Treatment was administered in a hyperbaric chamber at a pressure of 2.5 atm absolute. Each session lasted 90 min, and each course consisted of 20 daily sessions. Complete healing occurred in 5 patients after one to two courses. In an additional 2, after three courses, 1 patient improved but did not heal, and 2 did not improve. No adverse effects were noted by any of the 10 patients. Follow-up of 18 months did not reveal any recurrence. These preliminary results confirm that HBO therapy is a safe and efficient therapeutic option for perianal Crohn's disease.

Entities:  

Mesh:

Year:  1994        PMID: 7806829     DOI: 10.1097/00004836-199410000-00006

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  23 in total

1.  Hyperbaric oxygen in systemic inflammatory response.

Authors:  Haim Bitterman; Claus-Martin Muth
Journal:  Intensive Care Med       Date:  2004-03-18       Impact factor: 17.440

Review 2.  Managing Perianal Crohn’s Disease.

Authors:  Dawn M Wiese; David A Schwartz
Journal:  Curr Gastroenterol Rep       Date:  2012-04

3.  Management of nonhealing perineal wounds.

Authors:  Jill C Genua; David A Vivas
Journal:  Clin Colon Rectal Surg       Date:  2007-11

4.  Hyperbaric oxygenation ameliorates indomethacin-induced enteropathy in rats by modulating TNF-alpha and IL-1beta production.

Authors:  Z Yang; J Nandi; J Wang; G Bosco; M Gregory; C Chung; Y Xie; X Yang; E M Camporesi
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

5.  Perianal Crohn's Disease.

Authors:  Abhijit Basu; Steven D. Wexner
Journal:  Curr Treat Options Gastroenterol       Date:  2002-06

Review 6.  Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy.

Authors:  Julián Panés; Jordi Rimola
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-09       Impact factor: 46.802

7.  Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn's disease.

Authors:  G Weisz; A Lavy; Y Adir; Y Melamed; D Rubin; S Eidelman; S Pollack
Journal:  J Clin Immunol       Date:  1997-03       Impact factor: 8.317

8.  Hyperbaric oxygen: a novel modality to ameliorate experimental colitis.

Authors:  D Rachmilewitz; F Karmeli; E Okon; I Rubenstein; O S Better
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

9.  The effect of iNOS inhibitors and hyperbaric oxygen treatment in a rat model of experimental colitis.

Authors:  Cemal Nuri Ercin; Zeki Yesilova; Ahmet Korkmaz; Ayhan Ozcan; Cagatay Oktenli; Ahmet Uygun
Journal:  Dig Dis Sci       Date:  2008-10-30       Impact factor: 3.199

Review 10.  Bench-to-bedside review: oxygen as a drug.

Authors:  Haim Bitterman
Journal:  Crit Care       Date:  2009-02-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.